Go or no go? Pandemic looms over FDA timelines
Approval decisions are due for Jazz, Gilead and Galapagos in July, while Glaxo is preparing for a panel.
Merck and Pfizer square up for pneumococcal vaccine fight
The rivals have taken different strategies with next-gen pneumococcal vaccines, which will be fighting for a blockbuster market that is Pfizer’s to lose.
Big pharma sports smallest late-stage pipeline for a decade
The number of novel, pivotal-stage projects in big pharma pipelines has plunged – just as Covid-19 put the brakes on deal making.
Here come the anti-Covid antibodies
Behind Lilly’s LY-CoV555 come numerous biopharma antibody projects bidding to enter clinical development.
Chinook marks an ignominious end for Sting
Aduro finally runs up the white flag on Sting agonism, and becomes a listed shell for Chinook Therapeutics.
Asco 2020 – J&J sees multiple myeloma responses deepen
In anti-BCMA therapy Johnson & Johnson looks to have upstaged Bristol Myers Squibb again, and both companies have backups.
Merck joins Covid-19 pack with vaccine and antiviral deals
Merck & Co might have got off to a slow start, but now hopes to make up for lost time with multiple projects.
Careful label reading reveals more Lynparza doubts
Close analysis of the Parp inhibitor’s pivotal prostate cancer trial raises additional questions over this week’s US approval.
J&J holds its own on sales per employee
Johnson & Johnson is easily the largest big pharma employer, and on certain metrics outstrips smaller rivals.
